263 results on '"Hoogendoorn, Mels"'
Search Results
2. New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment – An oncogeriatric perspective
3. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
4. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
5. Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world
6. Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy
7. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial
8. Improving the identification of frail elderly newly diagnosed multiple myeloma patients
9. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features
10. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study
11. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
12. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
13. No decrease in fracture risk despite 15 years of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study
14. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
15. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
16. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population
17. New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment – An oncogeriatric perspective
18. Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients
19. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
20. No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status
21. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion
22. New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients
23. Native aortic valve endocarditis with Morganella morganii in a patient with multiple myeloma and valvular amyloidosis: a case report
24. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
25. High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population
26. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
27. Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population
28. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands
29. Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study
30. MYC expression and translocation analyses in low‐grade and transformed follicular lymphoma
31. Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes
32. Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival
33. Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
34. A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study
35. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
36. The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
37. The GLOW trial in chronic lymphocytic leukaemia
38. Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial
39. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial
40. Monitoring of Plasma Ferritin Levels after Blood Transfusions in Patients with Myelodysplastic Syndromes
41. Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes.
42. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients
43. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura
44. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
45. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder?
46. Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes.
47. Web-Based Return of Individual Patient-Reported Outcome Results Among Patients With Lymphoma: Randomized Controlled Trial (Preprint)
48. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
49. Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study
50. Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.